Medarex
To see an up-to date selection of historical analyses and insights on
Medarex,
visit our
new, dynamically updated Company Summary report pages for Medarex.
As a Guest User, you will have FREE access to a selection of historical analyses
and insights from EvaluatePharma®.
How to access FREE content
- Search the content using the search box at the top of every page
- Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
- Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar
Register for FREE to access even more content including 2007
Product Sales and Rankings.
A small selected sample of reports and related news headlines for
Medarex are available below.
Free sample reports are also available for other Companies.
To find out how you can access more detailed information on
Medarex,
or on any other Company covered by EvaluatePharma® Contact Us today.
NEWS - Selected Product News Headlines (as of 11 June 2008)
|
| Ilaris® Recommended for European Approval as New Biologic Drug to Treat a Rare but Serious Group of Auto-inflammatory Diseases
|
(Novartis)
|
(Invalid Date)
|
| Genmab Announces Lift of Zalutumumab Partial Clinical Hold
|
(Genmab)
|
(Invalid Date)
|
| Medarex to Receive Milestone Payment from FibroGen for the Initiation of a Phase 2 Study of FG-3019 in Patients with Diabetic Kidney Disease
|
(Medarex)
|
(Invalid Date)
|
| Recruitment Completed in Arzerra™ (ofatumumab) Pivotal CLL Study
|
(Genmab)
|
(Invalid Date)
|
| Simponi(™) (Golimumab) Receives Positive Opinion From CHMP For Once-Monthly Subcutaneous Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis
|
(Johnson & Johnson)
|
(Invalid Date)
|
| SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
|
(Schering-Plough)
|
(Invalid Date)
|
| Medarex buoyed by optimism but nervousness likely to creep in
|
(Medarex)
|
(Invalid Date)
|
| New Biological Therapy Ilaris® Approved in US to Treat Children and Adults With CAPS, a Serious Life-long Auto-inflammatory Disease
|
(Novartis)
|
(Invalid Date)
|
| FDA Extends Review of Arzerra(™) (Ofatumumab)
|
(GlaxoSmithKline)
|
(Invalid Date)
|
| FDA Extends Review of Arzerra(™) (Ofatumumab)
|
(Genmab)
|
(Invalid Date)
|
| FibroGen Begins Enrollment of Phase 2 Study of FG-3019, Monoclonal Antibody Against CTGF, in Patients with Diabetic Kidney Disease
|
(FibroGen)
|
(Invalid Date)
|
| Therapeutic focus – Lupus needs shots on goal to hit the mark
|
(Human Genome Sciences)
|
(Invalid Date)
|
| Recruitment Completed in Zalutumumab Head and Neck Cancer Pivotal Study
|
(Genmab)
|
(Invalid Date)
|
| New Analysis Shows Efficacy of Simponi(™) (GOLIMUMAB) in Anti-TNF Experienced Rheumatoid Arthritis Patients
|
(Schering-Plough)
|
(Invalid Date)
|
| Two-Year Data Show Patients Receiving Simponi(™) (GOLIMUMAB) Experienced Sustained Improvements in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondyitis
|
(Schering-Plough)
|
(Invalid Date)
|
| New Analysis Shows Efficacy of SIMPONI(TM) (Golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
|
(Johnson & Johnson)
|
(Invalid Date)
|
| Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis
|
(Johnson & Johnson)
|
(Invalid Date)
|
| ASCO EventAnalyzer - 2009's winners and losers
|
(Antigenics)
|
(Invalid Date)
|
| Genmab Announces Partial Clinical Hold on Zalutumumab Studies
|
(Genmab)
|
(Invalid Date)
|
| One-Year Phase III Study Confirms Ilaris® Offers Long-Term Remission in Patients With CAPS, a Severe Lifelong Auto-Inflammatory Disease
|
(Novartis)
|
(Invalid Date)
|
| Data from Ongoing Phase 1 Expansion Cohort and Multi-dose Phase 1b Trials of Investigational Fully Human Anti-PD-1 Antibody “ONO-4538/MDX-1106” in Cancer Patients at American Society of Clinical Oncology Annual Meeting
|
(Ono Pharmaceutical)
|
(Invalid Date)
|
| Investigational Antibody Treatment to Prevent C. difficile Recurrence Highlighted at Digestive Disease Week 2009
|
(Medarex)
|
(Invalid Date)
|
| Medarex Announces Efficacy Data in Cancer Patients Treated with Investigational Anti-PD-1 Antibody at American Society of Clinical Oncology Annual Meeting
|
(Medarex)
|
(Invalid Date)
|
| Celldex Therapeutics Announces CDX-1307 Clinical Data at 45th Annual ASCO Meeting
|
(Celldex Therapeutics)
|
(Invalid Date)
|
| Results from Three Phase 2 Studies Reported a Two-year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated With Ipilimumab (10 Mg/kg)
|
(Bristol-Myers Squibb)
|
(Invalid Date)
|
| Results from Three Phase 2 Studies Reported a Two-Year Survival Rate Ranging from 30 to 42 Percent in Metastatic Melanoma Patients Treated with Ipilimumab (10 mg/kg)
|
(Medarex)
|
(Invalid Date)
|
| Pfizer and Celldex Therapeutics Present Update on CDX-110 (PF-04948568) Phase 2 Brain Cancer Studies at 45th Annual ASCO Meeting
|
(Celldex Therapeutics)
|
(Invalid Date)
|
| FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's ARZERRA(TM) (Ofatumumab)
|
(GlaxoSmithKline)
|
(Invalid Date)
|
| FDA Advisory Panel Makes Favorable Recommendation for GlaxoSmithKline and Genmab's Arzerra(TM) (Ofatumumab)
|
(Genmab)
|
(Invalid Date)
|
| Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
|
(Medarex)
|
(Invalid Date)
|
| FDA Extends Review Timeline for STELARA(™) (Ustekinumab) Biologic License Application by Three Months
|
(Johnson & Johnson)
|
(Invalid Date)
|
| Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
|
(Medarex)
|
(Invalid Date)
|
| FDA Advisory Committee to Review Arzerra(™) (Ofatumumab)
|
(Genmab)
|
(Invalid Date)
|
| Simponi approval could spur J&J into legal action
|
(Johnson & Johnson)
|
(Invalid Date)
|
| Simponi(™) (Golimumab) Receives FDA Approval As First Once- Monthly Anti-TNF For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis
|
(Johnson & Johnson)
|
(Invalid Date)
|
| Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer
|
(Medarex)
|
(Invalid Date)
|
| Medarex Announces Clinical Data for MDX-1401 in Hodgkin's Lymphoma at Annual Meeting of the American Association for Cancer Research
|
(Medarex)
|
(Invalid Date)
|
| Health Canada Approves Simponi(™) (Golimumab) For Treatment Of Rheumatoid Arthritis, Psoriatic Arthritis And Ankylosing Spondylitis
|
(Johnson & Johnson)
|
(Invalid Date)
|
| Arzerra(™) (Ofatumumab) Granted Priority Review by FDA
|
(Genmab)
|
(Invalid Date)
|
| Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
|
(PharmAthene)
|
(Invalid Date)
|
| Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City
|
(Medarex)
|
(Invalid Date)
|
| Arzerra(™) (ofatumumab) MAA Accepted by EMEA
|
(Genmab)
|
(Invalid Date)
|
| PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
|
(PharmAthene)
|
(Invalid Date)
|
|
|
|
EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx
(prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings,
annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts
for marketed and emerging products are built-up using recent research reports from top equity analysts.
Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I,
phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy,
patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates,
deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age -
plus many more data items and analytics unique to EvaluatePharma®.
Aggregations of these measures at a high-level means that companies may be ranked against each other on items
such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs
organic sales), sales by therapy area or technology and various other concentration measures. These
aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.
Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available
Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.
